Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making
Purpose of Review Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss...
Gespeichert in:
| Veröffentlicht in: | Current heart failure reports 2019-12, Vol.16 (6), p.274-284 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 284 |
|---|---|
| container_issue | 6 |
| container_start_page | 274 |
| container_title | Current heart failure reports |
| container_volume | 16 |
| creator | Ebong, Imo Mazimba, Sula Breathett, Khadijah |
| description | Purpose of Review
Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation.
Recent Findings
N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation.
Summary
There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation. |
| doi_str_mv | 10.1007/s11897-019-00447-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6935320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2315970494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-17d6e0f97fbe09d5756cc869f5ae273eb9425b6b49ef73b2e8f96c8628fb16a83</originalsourceid><addsrcrecordid>eNp9kU1v1DAQhiMEoh_wBzggH7m42LFjxxyQli1lK61UDoWr5TiTrdvEDnbSVf89pikruPQ01swzr2fmLYp3lJxRQuTHRGmtJCZUYUI4l3j_ojimFRdYVVy9PLwZOSpOUrolpFRSqNfFEaOS05LR42Jcm9g6Y9EXFwYT7yAm5DxatffGW2jRBkyc0IVx_RzhE9qEPVobj65v4AFdDqOxE7qaI_oeAU_R-DT2xk8oLJntz9U5OgfrkgseD-bO-d2b4lVn-gRvn-Jp8ePi6_V6g7dX3y7Xqy22nIsJU9kKIJ2SXQNEtZWshLW1UF1loJQMGsXLqhENV9BJ1pRQd0pkoKy7hgpTs9Pi86I7zs0ArQWf5-v1GF1e80EH4_T_Fe9u9C7ca6FYxUqSBT48CcTwa4Y06cElC31eEMKcdD5fpSThime0XFAbQ0oRusM3lOg_VunFKp2t0o9W6X1uev_vgIeWv95kgC1AyiW_g6hvwxx9Ptpzsr8BSMmgzA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2315970494</pqid></control><display><type>article</type><title>Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making</title><source>Springer Nature - Complete Springer Journals</source><creator>Ebong, Imo ; Mazimba, Sula ; Breathett, Khadijah</creator><creatorcontrib>Ebong, Imo ; Mazimba, Sula ; Breathett, Khadijah</creatorcontrib><description>Purpose of Review
Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation.
Recent Findings
N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation.
Summary
There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation.</description><identifier>ISSN: 1546-9530</identifier><identifier>EISSN: 1546-9549</identifier><identifier>DOI: 10.1007/s11897-019-00447-w</identifier><identifier>PMID: 31741231</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biomarkers of Heart Failure (WH Tang & J Grodin ; Cardiac Surgery ; Cardiology ; Imaging ; Internal Medicine ; Medicine ; Medicine & Public Health ; Radiology ; Section Editors ; Topical Collection on Biomarkers of Heart Failure ; Vascular Surgery</subject><ispartof>Current heart failure reports, 2019-12, Vol.16 (6), p.274-284</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-17d6e0f97fbe09d5756cc869f5ae273eb9425b6b49ef73b2e8f96c8628fb16a83</citedby><cites>FETCH-LOGICAL-c446t-17d6e0f97fbe09d5756cc869f5ae273eb9425b6b49ef73b2e8f96c8628fb16a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11897-019-00447-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11897-019-00447-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31741231$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ebong, Imo</creatorcontrib><creatorcontrib>Mazimba, Sula</creatorcontrib><creatorcontrib>Breathett, Khadijah</creatorcontrib><title>Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making</title><title>Current heart failure reports</title><addtitle>Curr Heart Fail Rep</addtitle><addtitle>Curr Heart Fail Rep</addtitle><description>Purpose of Review
Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation.
Recent Findings
N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation.
Summary
There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation.</description><subject>Biomarkers of Heart Failure (WH Tang & J Grodin</subject><subject>Cardiac Surgery</subject><subject>Cardiology</subject><subject>Imaging</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Radiology</subject><subject>Section Editors</subject><subject>Topical Collection on Biomarkers of Heart Failure</subject><subject>Vascular Surgery</subject><issn>1546-9530</issn><issn>1546-9549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kU1v1DAQhiMEoh_wBzggH7m42LFjxxyQli1lK61UDoWr5TiTrdvEDnbSVf89pikruPQ01swzr2fmLYp3lJxRQuTHRGmtJCZUYUI4l3j_ojimFRdYVVy9PLwZOSpOUrolpFRSqNfFEaOS05LR42Jcm9g6Y9EXFwYT7yAm5DxatffGW2jRBkyc0IVx_RzhE9qEPVobj65v4AFdDqOxE7qaI_oeAU_R-DT2xk8oLJntz9U5OgfrkgseD-bO-d2b4lVn-gRvn-Jp8ePi6_V6g7dX3y7Xqy22nIsJU9kKIJ2SXQNEtZWshLW1UF1loJQMGsXLqhENV9BJ1pRQd0pkoKy7hgpTs9Pi86I7zs0ArQWf5-v1GF1e80EH4_T_Fe9u9C7ca6FYxUqSBT48CcTwa4Y06cElC31eEMKcdD5fpSThime0XFAbQ0oRusM3lOg_VunFKp2t0o9W6X1uev_vgIeWv95kgC1AyiW_g6hvwxx9Ptpzsr8BSMmgzA</recordid><startdate>20191201</startdate><enddate>20191201</enddate><creator>Ebong, Imo</creator><creator>Mazimba, Sula</creator><creator>Breathett, Khadijah</creator><general>Springer US</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191201</creationdate><title>Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making</title><author>Ebong, Imo ; Mazimba, Sula ; Breathett, Khadijah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-17d6e0f97fbe09d5756cc869f5ae273eb9425b6b49ef73b2e8f96c8628fb16a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Biomarkers of Heart Failure (WH Tang & J Grodin</topic><topic>Cardiac Surgery</topic><topic>Cardiology</topic><topic>Imaging</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Radiology</topic><topic>Section Editors</topic><topic>Topical Collection on Biomarkers of Heart Failure</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ebong, Imo</creatorcontrib><creatorcontrib>Mazimba, Sula</creatorcontrib><creatorcontrib>Breathett, Khadijah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current heart failure reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ebong, Imo</au><au>Mazimba, Sula</au><au>Breathett, Khadijah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making</atitle><jtitle>Current heart failure reports</jtitle><stitle>Curr Heart Fail Rep</stitle><addtitle>Curr Heart Fail Rep</addtitle><date>2019-12-01</date><risdate>2019</risdate><volume>16</volume><issue>6</issue><spage>274</spage><epage>284</epage><pages>274-284</pages><issn>1546-9530</issn><eissn>1546-9549</eissn><abstract>Purpose of Review
Decision-making in advanced heart failure (HF) is a complex process that involves careful consideration of competing tradeoffs of risks and benefits in regard to heart transplantation (HT) or left ventricular assist device (LVAD) placement. The purpose of this review is to discuss how biomarkers may affect decision-making for HT or LVAD implantation.
Recent Findings
N-Terminal probrain natriuretic peptide, soluble suppression of tumorigenicity-2, galectin-3, copeptin, and troponin T levels are associated with HF survival and can help identify the appropriate timing for advanced HF therapies. Patients at risk of right ventricular failure after LVAD implantation can be identified with preimplant biomarkers of extracellular matrix turnover, neurohormonal activation, and inflammation.
Summary
There is limited data on the adoption of biomarker measurement for decision-making in the allocation of advanced HF therapies. Nonetheless, biomarkers can improve risk stratification and prognostication thereby optimizing patient selection for HT and LVAD implantation.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>31741231</pmid><doi>10.1007/s11897-019-00447-w</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1546-9530 |
| ispartof | Current heart failure reports, 2019-12, Vol.16 (6), p.274-284 |
| issn | 1546-9530 1546-9549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6935320 |
| source | Springer Nature - Complete Springer Journals |
| subjects | Biomarkers of Heart Failure (WH Tang & J Grodin Cardiac Surgery Cardiology Imaging Internal Medicine Medicine Medicine & Public Health Radiology Section Editors Topical Collection on Biomarkers of Heart Failure Vascular Surgery |
| title | Cardiac Biomarkers in Advanced Heart Failure: How Can They Impact Our Pre-transplant or Pre-LVAD Decision-making |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A27%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20Biomarkers%20in%20Advanced%20Heart%20Failure:%20How%20Can%20They%20Impact%20Our%20Pre-transplant%20or%20Pre-LVAD%20Decision-making&rft.jtitle=Current%20heart%20failure%20reports&rft.au=Ebong,%20Imo&rft.date=2019-12-01&rft.volume=16&rft.issue=6&rft.spage=274&rft.epage=284&rft.pages=274-284&rft.issn=1546-9530&rft.eissn=1546-9549&rft_id=info:doi/10.1007/s11897-019-00447-w&rft_dat=%3Cproquest_pubme%3E2315970494%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2315970494&rft_id=info:pmid/31741231&rfr_iscdi=true |